SCHEMBL10219827

SCHEMBL10219827

O=C(O)c1cccc(-c2nc3cc(-c4nc5cc(Cl)ccc5o4)ccc3n2C2CCOCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 7/20 0.49
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
USP2 O75604 1/20 0.45
MAPK1 P28482 1/20 0.45
AHR P35869 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
PARP3 Q9Y6F1 1/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.41
FASN P49327 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10219866 0.92 HPSE (0.45) HPSESMN1; SMN2KDM4EHPGDUSP2
SCHEMBL2687370 0.91 RPS6KB1 (0.45) SMN1; SMN2KDM4EHPGDUSP2MAPK1
SCHEMBL2688580 0.86 KDM4E (0.54) SMN1; SMN2KDM4EHPGDUSP2MAPK1
SCHEMBL2687597 0.84 RPS6KB1 (0.47) HPSESMN1; SMN2KDM4EHPGDUSP2
SCHEMBL2687682 0.83 CNR1 (0.44) SMN1; SMN2KDM4EHPGDHSD17B10CASP3
SCHEMBL2687130 0.82 CASP3 (0.61) SMN1; SMN2KDM4EHPGDUSP2MAPK1
SCHEMBL2698006 0.81 L3MBTL1 (0.60) HPSEUSP2HSD17B10L3MBTL1
SCHEMBL2686940 0.81 KDM4E (0.51) SMN1; SMN2KDM4EHPGDUSP2MAPK1
SCHEMBL2689825 0.80 PARP3 (0.42) SMN1; SMN2KDM4EHPGDUSP2MAPK1
SCHEMBL2686059 0.80 OPRM1 (0.43) SMN1; SMN2KDM4EHPGDCASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
WO-2010137349-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS 住友化学株式会社 (JP) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 HPSE 1880/4885SMN1; SMN2 157/4885KDM4E 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.